Histone Demethylase

There are two classes of enzymes involved in histone methylation: methyltransferases and demethylases. While methyltransferases are responsible for establishing methylation patterns, demethylases are capable of removing methyl groups not only from histones but other proteins as well. Histone demethylases not only target methylated sites on histone tails but also interact with methylated sites on non-histone proteins, such as p53.

Histone lysine demethylases (KDMs) are of interest as drug targets due to their regulatory roles in chromatin organization and their tight associations with diseases including cancer and mental disorders.

JMJD1A (also named KDM3A) is a demethylasethat removes methyl from histone lysine H3K9. It plays important roles in various cellular processes, including spermatogenesis, energy metabolism, regulation of stem cell and gender display.

Jumonji domain-containing 3 (Jmjd3) has been identified as a histone demethylase, which specifically catalyzes the removal of methylation from H3K27me3.

(rel)-Tranylcypromine D5 hydrochloride

(2-Phenylcyclopropylamine D5 hydrochloride)

Cat. No.: HY-17447SA

(rel)-Tranylcypromine D5 hydrochloride (2-Phenylcyclopropylamine D5 hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride.



Relative stereochemistry

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

2,4-PDCA

Cat. No.: HY-W017132

2,4-PDCA (2,4 pyridine dicarboxylic acid) is a broad-spectrum inhibitor of **2OG oxygenase**, including **JmjC domain-containing family of histone demethylases (JHDMs)**. 2,4-PDCA is a target chemical in the field of bio-based plastics.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS8351

(NSC51355)

Cat. No.: HY-100744

AS8351 (NSC51355) is a **KDM5B** inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bizine

Cat. No.: HY-121095

Bizine, a Phenelzine analogue, is a potent and selective **LSD1** inhibitor, with a b>K_i of 59 nM. Bizine can modulate bulk histone methylation in cancer cells. Bizine shows neuroprotective effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bomedemstat

(IMG-7289)

Cat. No.: HY-109169

Bomedemstat (IMG-7289) is an orally active and irreversible inhibitor of the epigenetically active lysine-specific demethylase 1 (LSD1) in mouse models of myeloproliferative neoplasms (MPNs).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bomedemstat ditosylate

(IMG-7289 ditosylate)

Cat. No.: HY-109169A

Bomedemstat (IMG-7289) ditosylate is an oral and irreversible inhibitor of the epigenetically active lysine-specific demethylase 1 (LSD1) in mouse models of myeloproliferative neoplasms (MPNs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBB1003

Cat. No.: HY-15774

CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM. IC50 value: 10.54 uM Target: LSD1 inhibitor in vitro: Treatment of F9 cells with CBB1003 led to the activation of CHRM4 and SCN3A expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBB1003 hydrochloride

Cat. No.: HY-15774A

CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM. IC50 value: 10.54 uM Target: LSD1 inhibitor in vitro: Treatment of F9 cells with CBB1003 led to the activation of CHRM4 and SCN3A expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBB1007

Cat. No.: HY-15313

CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBB1007 hydrochloride

Cat. No.: HY-15313B

CBB1007 Hcl is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CBB1007 trihydrochloride

Cat. No.: HY-15313C

CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).



Purity: 96.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Corin

Cat. No.: HY-111048

Corin is a dual inhibitor of histone lysine specific demethylase **(LSD1)** and histone deacetylase **(HDAC)**, with a K_I**(inact)** of 110 nM for LSD1 and an IC_{50} of 147 nM for HDAC1.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CPI-455

Cat. No.: HY-100421

CPI-455 is a specific, pan-**KDM5** inhibitor with an **IC_{50}** of 10 nM for KDM5A.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Daminozide

Cat. No.: HY-13643

Daminozide, a plant growth regulator, is a selective inhibitor of the human **KDM2/7 histone demethylases**, with **IC_{50}**s of 0.55, 1.5 and 2.1 μM for **PHF8**, **KDM2A**, and **KIAA1718**, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

DDP-38003 dihydrochloride

Cat. No.: HY-19612A

DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (**KDM1A/LSD1**) with an **IC_{50}** of 84 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDP-38003 trihydrochloride

Cat. No.: HY-19612B

DDP-38003 trihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (**KDM1A/LSD1**) with an **IC_{50}** of 84 nM.



Purity: 96.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Eicosapentaenoic Acid

(EPA; Timnodonic acid)

Cat. No.: HY-B0660

Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA).

Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Eicosapentaenoic Acid sodium

(EPA sodium; Timnodonic acid sodium)

Cat. No.: HY-W011269

Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA).

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Eicosapentaenoic Acid-d5

(EPA-d5; Timnodonic acid-d5)

Cat. No.: HY-B0660S

Eicosapentaenoic Acid-d5 (EPA-d5) is the deuterium labeled Eicosapentaenoic Acid. Eicosapentaenoic Acid (EPA; Timnodonic acid) is an omega-3 fatty acid.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK 690 Hydrochloride

Cat. No.: HY-117226A

GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 **(LSD1)**, with a K_d value of 9 nM and a biochemical **IC_{50}** of 37 nM.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK-J1

Cat. No.: HY-15648

GSK-J1 is a potent inhibitor of **H3K27me3/me2-demethylases JMJD3/KDM6B** and **UTX/KDM6A**, with IC_{50} of 60 nM towards KDM6B. .



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

GSK-J1 lithium salt

Cat. No.: HY-15648D

GSK-J1 lithium salt is a potent inhibitor of **H3K27me3/me2-demethylases JMJD3/KDM6B** and **UTX/KDM6A**, with IC_{50} of 60 nM towards KDM6B.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

GSK-J4

Cat. No.: HY-15648B

GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases **JMJD3/KDM6B** and **UTX/KDM6A** with IC_{50}s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC_{50} of 9 μM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

GSK-J4 hydrochloride

Cat. No.: HY-15648F

GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases **JMJD3/KDM6B** and **UTX/KDM6A** with IC_{50}s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC_{50} of 9 μM.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

GSK-LSD1 dihydrochloride

Cat. No.: HY-100546A

GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (**LSD1**) inhibitor with an IC_{50} of 16 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GSK-LSD1-d4 dihydrochloride

Cat. No.: HY-100546AS

GSK-LSD1-d4 dihydrochloride is the deuterium labeled GSK-LSD1 dihydrochloride. GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (**LSD1**) inhibitor with an IC_{50} of 16 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK2879552

Cat. No.: HY-18632

GSK2879552 an orally active, selective and irreversible inhibitor of **lysine specific demethylase 1 (LSD1/ KDM1A)**, with potential antineoplastic activity.



Purity: >98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2879552 dihydrochloride

Cat. No.: HY-18632A

GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of **lysine specific demethylase 1 (LSD1/KDM1A)**, with potential antineoplastic activity.



Purity: 99.52%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK467

Cat. No.: HY-116761

GSK467 is a cell penetrant and selective **KDM5B (JARID1B or PLU1)** inhibitor with a K_i of 10 nM, shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HDAC6-IN-3

Cat. No.: HY-145259

HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active **HDAC6** inhibitor with IC_{50}s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective **MAO-A** (IC_{50}=0.79 μM) and **LSD1** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iadademstat dihydrochloride (ORY-1001 dihydrochloride; RG6016 dihydrochloride; RO 7051790 dihydrochloride)

Cat. No.: HY-12782T

Iadademstat (ORY-1001) dihydrochloride is a selective irreversible lysine (K)-specific demethylase 1A (**KDM1A/LSD1**) inhibitor.



Purity: 98.30%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

INCB059872

Cat. No.: HY-141677

INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (**LSD1**) inhibitor. INCB059872 can be used for the research of myeloid leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IOX1

Cat. No.: HY-12304

IOX1, 5-Carboxy-8-hydroxyquinoline, is a potent broadspectrum inhibitor of **2OG** oxygenases, including the **JmjC** demethylases. IOX1 inhibits KDM4C, KDM4E, KDM2A, KDM3A and KDM6B with IC_{50} values of 0.6 μM, 2.3 μM, 1.8 μM, 0.1 μM and 1.4 μM, respectively. IOX1 also inhibits ALKBH5.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JIB-04

Cat. No.: HY-13953

JIB-04 is a pan-selective **Jumonji histone demethylase** inihibitor with IC_{50}s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

JMJD7-IN-1

Cat. No.: HY-132198

JMJD7-IN-1 is a potent **JMJD7** inhibitor, with an IC_{50} of 6.62 μM. JMJD7-IN-1 shows good inhibitory activity against cells expressing a high level of JMJD7.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JQKD82 (JADA82; PCK82)

Cat. No.: HY-138691

JQKD82 (JADA82) is a cell-permeable and selective **KDM5** inhibitor. JQKD82 increases H3K4me3 and can be used for the research of multiple myeloma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM2/7-IN-1

Cat. No.: HY-107573

KDM2/7-IN-1 (TC-E 5002) is a selective histone demethylase **KDM2/7** subfamily inhibitor (IC_{50} values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM2A/7A-IN-1

Cat. No.: HY-108706

KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of **histone lysine demethylases KDM2A/7A**, with an IC_{50} of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone...



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KDM2B-IN-3

Cat. No.: HY-139600

KDM2B-IN-3 is a **histone demethylase KDM2B** inhibitor extracted from patent WO2016112284A1, compound 183c. KDM2B-IN-3 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM2B-IN-4

Cat. No.: HY-139601

KDM2B-IN-4 is a **histone demethylase KDM2B** inhibitor extracted from patent WO2016112284A1, compound 182b. KDM2B-IN-4 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM4-IN-2

Cat. No.: HY-128343

KDM4-IN-2 (Compound 19a) is a potent and selective **KDM4/KDM5** dual inhibitor with K_is of 4 and 7 nM for KDM4A and KDM5B, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM4-IN-3

Cat. No.: HY-132896

KDM4-IN-3 is a **KDM4** inhibitor that exhibits improved potency in biochemical assays, is cell-permeable, and kills prostate cancer cells at low micromolar concentrations.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM4D-IN-1

Cat. No.: HY-101928

KDM4D-IN-1 is a new **histone lysine demethylase 4D** (**KDM4D**) inhibitor with an IC_{50} value of 0.41±0.03 μM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KDM5-C70

Cat. No.: HY-120400

KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-**KDM5 histone demethylase** inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 100 mg, 250 mg

KDM5-IN-1

Cat. No.: HY-100422

KDM5-IN-1 is a potent, selective and orally bioavailable **KDM5** inhibitor with an IC_{50} of 15.1 nM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KDM5A-IN-1

Cat. No.: HY-100014

KDM5A-IN-1 is a potent, orally bioavailable pan-**histone lysine demethylases 5 (KDM5)** inhibitor with IC_{50}s of 45 nM, 56 nM and 55 nM for **KDM5A**, **KDM5B** and **KDM5C**, respectively, and with an EC_{50} value of 960 nM for PC9 H3K4Me3.



Purity: 95.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KDOAM-25

Cat. No.: HY-102047

KDOAM-25 is a potent and highly selective **histone lysine demethylases 5 (KDM5)** inhibitor with IC_{50}s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

KDOAM-25 citrate

Cat. No.: HY-102047B

KDOAM-25 citrate is a potent and highly selective **histone lysine demethylases 5 (KDM5)** inhibitor with IC_{50}s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively.



Purity: 95.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

KDOAM-25 trihydrochloride

Cat. No.: HY-102047A

KDOAM-25 trihydrochloride is a potent and highly selective **histone lysine demethylases 5 (KDM5)** inhibitor with IC_{50}s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-2-Hydroxyglutaric acid

((S)-2-Hydroxyglutaric acid)

Cat. No.: HY-113039

L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit **histone demethylases** and hence promote histone methylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

L-2-Hydroxyglutaric acid disodium

((S)-2-Hydroxyglutaric acid disodium) Cat. No.: HY-W015114

L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit **histone demethylases** and hence promote histone methylation.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

LSD1-IN-14

Cat. No.: HY-145861

LSD1-IN-14 is a potent and selective **LSD1** inhibitor (IC_{50}=0.89 μM). LSD1-IN-14 can significantly inhibit the proliferation of A549 and THP-1 cells and induce the **apoptosis** of tumor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LSD1-IN-5

Cat. No.: HY-100859

LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (**LSD1**), with an IC_{50} of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LSD1-IN-6

Cat. No.: HY-100860

LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (**LSD1**), with an IC_{50} of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LSD1/HDAC6-IN-1

Cat. No.: HY-131970

LSD1/HDAC6-IN-1 is an orally active dual inhibitor of **lysine specific demethylase 1(LSD1)/Histone deacetylase 6 (HDAC6)**, with anti-tumor activity. LSD1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC4355

Cat. No.: HY-144905

MC4355 is a dual inhibitor of **EZH2** and histone deacetylase **(HDAC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML324

Cat. No.: HY-12725

ML324 is a potent **JMJD2** demethylase inhibitor with antiviral activity. ML324 also exhibits inhibition for the histone demethylase **KDM4B**, with an IC_{50} of 4.9 μM.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Namoline

Cat. No.: HY-115747

Namoline, a γ-pyrone, is a selective and reversible **Lysine-specific demethylase 1 (LSD1)** inhibitor with an IC50 of 51 μM in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NCGC00244536

(KDM4B Inhibitor B3) Cat. No.: HY-101799

NCGC00244536 is a potent **KDM4B** inhibitor with an IC_{50} of 10 nM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NCGC00247743

Cat. No.: HY-112308

NCGC00247743 is a histone lysine demethylase **KDM4** inhibitor.



Purity: 96.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

NSC636819

Cat. No.: HY-110154

NSC636819 is a competitive and selective inhibitor of **KDM4A/KDM4B**. KDM4A/KDM4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OG-L002

Cat. No.: HY-19333

OG-L002 is a potent and highly selective **LSD1** inhibitor with an IC_{50} of 0.02 μM. OG-L002 is a potent **monoamine oxidases (MAO)** inhibitor with IC_{50}s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of **HSV IE** genes.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PBIT

Cat. No.: HY-101451

PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (**JARID1**) enzymes. PBIT inhibits **JARID1B** (**KDM5B** or **PLU1**) histone demethylase with an IC_{50} of about 3 μM . PBIT also inhibits **JARID1A** and **JARID1C** with IC_{50}s of 6 μM and 4.9 μM, respectively.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PFI-90

Cat. No.: HY-139348

PFI-90 is a selective inhibitor of histone demethylase **(KDM3B)** that inhibits **PAX3-FOXO1** action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).



Purity: 95.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Procaine

Cat. No.: HY-B0546

Procaine is a **DNA-demethylating** agent. Procaine acts through multiple targets and has a slow onset and a short duration of action.



Purity: 99.07%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

Procaine hydrochloride

Cat. No.: HY-B0546A

Procaine hydrochloride is a **DNA-demethylating** agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action.



Purity: 99.94%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

Procaine-d4 hydrochloride

Cat. No.: HY-B0546AS

Procaine-d4 hydrochloride is the deuterium labeled Procaine hydrochloride. Procaine hydrochloride is a **DNA-demethylating** agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pulrodemstat

(CC-90011; LSD1-IN-7)

Cat. No.: HY-129388A

Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of **lysine specific demethylase-1 (LSD1)** with an IC_{50} of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pulrodemstat benzenesulfonate

(CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate) Cat. No.: HY-129388B

CC-90011 benzenesulfonate is a potent, selective, reversible and orally active inhibitor of **lysine specific demethylase-1 (LSD1)** with an IC_{50} of 0.25 nM. CC-90011 benzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B.



Purity: 99.39%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pulrodemstat Methylbenzenesulfonate (CC-90011

Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate) Cat. No.: HY-129388

CC-90011 Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of **lysine specific demethylase-1 (LSD1)** with an IC_{50} of 0.25 nM. CC-90011 Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

QC6352

Cat. No.: HY-104048

QC6352 is an orally available, selective and potent **KDM4C** inhibitor with an IC_{50} of 35 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RN-1 dihydrochloride

Cat. No.: HY-110130

RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective **lysine-specific demethylase 1 (LSD1)** inhibitor with an IC_{50} of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC_{50} values of 0.51 μM and 2.785 μM respectively.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

S2101

Cat. No.: HY-110277

S2101 is a **lysine-specific demethylase 1 (LSD1)** inhibitor with an IC_{50} of 0.99 μM, K_i of 0.61 μM and K_{inact}/K_i of 4560 M/s.



Relative stereochemistry

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

S2116

Cat. No.: HY-136522

S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent **lysine-specific demethylase 1 (LSD1)** inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S2157

Cat. No.: HY-136523

S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent **lysine-specific demethylase 1 (LSD1)** inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions.



Relative stereochemistry

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Seclidemstat

(SP-2577)

Cat. No.: HY-103713

Seclidemstat is a potent noncompetitive and reversible **KDM1A (LSD1)** inhibitor (K_i=31 nM, IC_{50}=13 nM).



Purity: 99.62%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Seclidemstat mesylate

(SP-2577 mesylate)

Cat. No.: HY-103713A

Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible **KDM1A (LSD1)** inhibitor (K_i=31 nM, IC_{50}=13 nM).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SKLB325

Cat. No.: HY-139782

SKLB325 is a Jumonji domain-containing 6 (**JMJD6**) inhibitor with a binding affinity (K_D) value of 0.755μM, and the IC_{50} value of 0.7797μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces **apoptosis**.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SP2509

Cat. No.: HY-12635

SP2509 is a potent and selective antagonist of **lysine specific demethylase 1 (LSD1)** with an IC_{50} of 13 nM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

T-3775440 hydrochloride

Cat. No.: HY-103085

T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase **(LSD1)** inhibitor with an IC_{50} value of 2.1 nM.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

T-448

Cat. No.: HY-122635A

T-448 is a specific, orally active and irreversible inhibitor of **lysine-specific demethylase 1 (LSD1, an H3K4 demethylase)**, with an IC_{50} of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

T-448 free base

Cat. No.: HY-122635

T-448 free base is a specific, orally active and irreversible inhibitor of **lysine-specific demethylase 1 (LSD1, an H3K4 demethylase)**, with an IC_{50} of 22 nM. T-448 free base enhances H3K4 methylation in primary cultured rat neurons.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAK-418

Cat. No.: HY-138830

TAK-418 is a selective, orally active **LSD1 (KDM1A)** enzyme inhibitor with an IC_{50} of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models.



Purity: 98.64%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tranylcypromine hemisulfate (dl-Tranylcypromine hemisulfate; trans-2-Phenylcyclopropylamine hemisulfate salt)

Cat. No.: HY-B1496

Tranylcypromine hemisulfate (dl-Tranylcypromine hemisulfate) is an irreversible, nonselective **monoamine oxidase (MAO)** inhibitor used in the treatment of depression.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Vafidemstat (ORY-2001)

Cat. No.: HY-112623

Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (**LSD1**)/**MAO-B** inhibitor.



Purity: 98.57%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

YUKA1

Cat. No.: HY-100764

YUKA1 is a potent and cell permeable Lysine demethylase 5A (**KDM5A**) inhibitor, with an IC_{50} of 2.66 μM, less active on KDM5C (IC_{50}, 7.12 μM), and is inactive on KDM5B, KDM6A or KDM6B. YUKA1 increases H3K4me3 levels in human cells with anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

α-Hydroxyglutaric acid (2-Hydroxyglutarate; 2-Hydroxyglutaric acid; 2-Hydroxypentanedioic acid)

Cat. No.: HY-113038B

α-Hydroxyglutaric acid (2-Hydroxyglutarate) is an α-hydroxy acid form of glutaric acid.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg (67.5 mM * 1 mL in Ethanol),